Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US,
|
|
- Elijah Preston
- 5 years ago
- Views:
Transcription
1 Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US, Rates of Prescription Painkiller Sales, Deaths, and Substance Abuse Treatment Admissions ( ) 7 Rate Sales per kilograms per 1, people Deaths per 1, people Treatment admissions per 1, people National Vital Statistics System ; Automation of Reports and Consolidated Orders System of the Drug Enforcement Administration ; Treatment Episode Data Set
2 National Treatment Gap: Worse in Rural Areas At least 1 buprenorphine provider No buprenorphine providers Currently Approved Medications for OUD Treatment Agent Dose Dosing Buprenorphine sublingual film, tablets (generic), implant Buprenorphine +naloxone sublingual tablet Methadone tablets/liquid (generic) Oral: 2 mg, 8 mg film and tablets Implant: 74.2 mg 2 mg buprenorphine with.5 mg naloxone, 4 mg/1 mg, 8 mg/2 mg, or 12 mg/3 mg Oral: 5 mg or 1 mg tablets; 1 mg/ml liquid Initial: 2 4 mg (increase by 2 4 mg) Daily: 8 mg Implant: 4 implants inserted subdermally every 6 months Maximum: 24 mg daily 16 mg/4 mg daily as maintenance dose Initial: 2 3 mg (reassess in 2 4 hours; add 1 mg as needed) Daily: 6 12 mg Naltrexone XR injection IM: 38 mg in 4 ml Every 4 weeks Naltrexone tablets (generic) Oral: 5 mg Daily: 5 mg (may give 2 3 daily doses at once on Monday Wednesday Friday); observation needed Naloxone Nasal spray: 4 mg in.1 ml IM/SC: 2 mg in.4 ml autoinjector As needed (emergency use) Buprenorphine ER injection (recently approved; formerly RBP 6) Once monthly depot SC injection, 3 mg/1.5 ml or 1 mg/.5 ml Two monthly initial doses of 3 mg followed by 1 mg monthly maintenance doses 2
3 Methadone μ opioid receptor agonist Side effects include lightheadedness, dizziness, sedation, nausea, vomiting, and sweating Risk of addiction, respiratory depression, fatal overdose, QTinterval prolongation, arrhythmia, and NOWS Drug interactions with benzodiazepines or CYP3A4, 2B6, 2C19, 2C9, and 2D6 inhibitors Patients Positive for Opioids, % 1% 8% 6% 4% 2% % Opioid Use With or Without Methadone Treatment Yancovitz et al, 1991 Vanichseni et al, 1991 Schwartz et al, 27 Kinlock et al, 27 Methadone Control Gruber et al, 28 Dolan et al, 23 Adapted from Yancovitz SR, et al. Am J Public Health. 1991;81: ; Vanichseni S, et al. Int J Addict. 1991;26:1313 2; Schwartz RP, et al. Drug Alcohol Depend. 27;86:3 6; Kinlock TW, et al. Drug Alcohol Depend. 27;91:22 7; Gruber VA, et al. Drug Alcohol Depend. 28;94:199 26; Dolan KA, et al. Drug Alcohol Depend. 23;72:59 65; Methadone Prescribing Information. Methadone Maintenance vs 18 Day Detoxification Proportion of Patients in Treatment M18 MMT Days in Treatment 4 5 Mean Days Used Proportion of Patients Using Heroin M18 MMT 1 Heroin Use in Previous 3 Days M18 MMT Illicit Opioid Use Monthly Assessment Sees KL, et al. JAMA. 2;283:
4 Buprenorphine Maintenance/Withdrawal: Mortality 2 No. Remaining in Treatment Buprenorphine Control 75% retention 75% UTS negative 2% mortality in placebo group Treatment Duration, days Kakko J, et al. Lancet. 23;361: Primary Care Based Buprenorphine Taper vs Maintenance Prescription OUD Treatment Retention, % of Patients Mean buprenorphine dosage, mg/d Maintenance condition Taper condition Treatment Retention and Mean Buprenorphine Dosage for Patients With Prescription Opioid Dependence Maintenance condition Taper condition Time in Study, weeks Completion of 14 week trial: taper 11% vs maintenance 66% Mean percentage of urine negative for opioids: taper 35% vs maintenance 53% Fiellin DA, et al. JAMA Intern Med. 214;174:
5 All Cause Mortality Rates In and Out of Opioid Substitution Treatment With Methadone or Buprenorphine and Overall Pooled All Cause Mortality Rates, No. of Deaths/Person Years All Cause Mortality Rate/1, Person Years (95% CI) In Treatment Out of Treatment All Cause Mortality Rate/1, Person Years (95% CI) In Treatment Out of Treatment Methadone Gearing et al, /14,474 33/1, ( ) 28.2 ( ) Cushman, /1,655 14/ ( ) 47.1 ( ) Grönbladh et al, /1,85 32/ ( ) 43.2 ( ) Caplehorn et al, /1,975 36/2, (2.8 1.) 15.8 ( ) Fugelstad et al, /242 5/ ( ) ( ) Fugelstad et al, /177 4/ ( ) 69.9 ( ) Scherbaum et al, 22 18/114 14/ ( ) 81.4 ( ) Fugelstad et al, 27 77/3,354 74/1, ( ) 56.5 ( ) Clausen et al, 28 9/6,45 46/1, ( ) 35.3 ( ) Degenhardt et al, /111, /15, ( ) 14.3 ( ) Cornish et al, 21 3/5,129 71/4, (4. 8.3) 16.6 ( ) Peles et al, 21 42/3,985 52/ ( ) 71.5 ( ) Evans et al, /25, /48, ( ) 17.6 ( ) Kimber et al, /91, /45, ( ) 12.4 ( ) Nosyk et al, /3,979 26/1, ( ) 13.2 ( ) Cousins et al, /22,648 98/6, ( ) 15.7 ( ) Overall 11.3 ( ) 36.1 ( ) Buprenorphine Cornish et al, 21 7/74 1/ ( ) 13.3 ( ) Reece, 21 3/119 4/6, (.6 7.8) 5.8 ( ) Kimber et al, /21, /31, ( ) 1.1 ( ) Overall 4.3 ( ) 9.5 ( ) In treatment Out of treatment Sordo L, et al. BMJ. 217;357:j by British Medical Journal Publishing Group Overdose Mortality Rates In and Out of Opioid Substitution Treatment With Methadone or Buprenorphine and Overall Pooled Overdose Mortality Rates, No. of Deaths/Person Years Overdose Mortality Rate/ Overdose Mortality Rate/ 1, Person Years (95% CI) In Treatment Out of Treatment 1, Person Years (95% CI) In Treatment Out of Treatment Methadone Gearing et al, /14,474 21/1, ( ) 17.9 ( ) Cushman, /1,655 7/ (.7 6.2) 23.6 ( ) Grönbladh et al, 199 7/1,85 27/ ( ) 36.5 ( ) Caplehorn et al, /1,792 19/2,4 2.2 (.6 5.7) 9.5 ( ) Buster et al, 22 42/18,747 26/1, (1.6 3.) 2.4 ( ) Scherbaum et al, 6/114 13/ ( ) 75.6 ( ) 22 Davoli et al, 27 7/5,751 9/ (.5 2.5) 9. ( ) Clausen et al, 28 24/6,45 28/1, ( ) 21.5 ( ) Peles et al, 21 5/3,985 13/ (.4 2.9) 17.9 ( ) Kimber et al, /91, /45, ( ) 4.8 ( ) Cousins et al, /22,648 24/6, ( ) 3.8 ( ) Overall 2.6 ( ) 12.7 ( ) Buprenorphine Kimber et al, /21, /31, (1. 2.) 4.6 ( ) In treatment Out of treatment Sordo L, et al. BMJ. 217;357:j by British Medical Journal Publishing Group 5
6 Naltrexone Efficacy Opioid Free Patients, % XR NTX (n = 126) Placebo (n = 124) Mean Change in Craving Score Patients With Full Retention, % Number at risk XR NTX Placebo 6 4 XR NTX (n = 126) 2 Placebo (n = 124) 2 4 P <.1 (adjusted) Treatment Duration, weeks XR NTX (n = 126) 3 Placebo (n = 124) 2 1 Log rank P =.42 (adjusted) Krupitsky E, et al. Lancet. 211;377: Naloxone Formulations: Injection/autoinjector Risk of recurrent respiratory and CNS depression, limited efficacy with partial agonists or mixed agonists/antagonists, precipitation of severe opioid withdrawal, and cardiovascular effects Adverse events include dizziness and injection site erythema Nasal spray Risk of recurrent respiratory and CNS depression, limited efficacy with partial agonists or mixed agonists/antagonists, precipitation of severe opioid withdrawal, and cardiovascular effects Adverse events include increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation No evidence that naloxone availability is associated with increased drug use 2 prospective studies found reductions in drug use among trained overdose responders Seal KH, et al. J Urban Health. 25;82:33 11; Wagner KD, et al. Int J Drug Policy. 21;21:186 93; Doe Simkins M, et al. BMC Public Health. 214;14:297. 6
7 Buprenorphine Extended Release Injection Formerly RBP 6 Phase 3 results: abstinence rates significantly higher vs placebo Most frequent AEs: headache, constipation, nausea, injection site pruritus, vomiting, insomnia, and upper respiratory tract infection Approved by the FDA on November 3, 217 Once monthly injectable formulation Learned S, et al. Presented at: College on Problems of Drug Dependence Annual Meeting; June 17 22, 217; Montreal. MAT in Pregnant/Breastfeeding Women OAT is the gold standard of treatment in pregnancy Buprenorphine has a better NAS profile OAT is recommended by the American College of Obstetricians and Gynecologists Not enough data on naltrexone Relapse rates in pregnant women taken off OAT are high NAS is treatable Breastfeeding and mother/neonate rooming in encouraged ACOG Committee on Health Care for Underserved Women. Obstet Gynecol. 212;119:17 76; Pritham UA, et al. J Obstet Gynecol Neonatal Nurs. 212;41:18 9; Welle Strand GK, et al. Acta Paediatr. 213;12:16 6; Wachman EM, et al. JAMA. 213;39:1821 7; Abdel Latif ME, et al. Pediatrics. 26;117:e
8 Comprehensive Addiction Treatment Cortex Role: Decision Making Intervention: Counseling Limbic Region Role: Drive Generation Intervention: Pharmacotherapy Why Aren t Physicians Prescribing? Providers Responding Yes, % Barriers to Prescribing Buprenorphine by Prescribing and Nonprescribing Physicians Lack of Psychosocial Support Time Constraints Lack of Specialty Backup Does not prescribe buprenorphine (N = 56) Prescribes buprenorphine (N = 22) Lack of Confidence Resistance From Practice Partners Lack of Institutional Support Concerns About Reimbursement Lack of Patient Need Hutchinson E, et al. Ann Fam Med. 214;12:
9 OAT: Terminology Physical Dependence Are Not Necessarily Equal Addiction Acknowledgment of Commercial Support This activity is supported by an educational grant from Indivior, Inc. Contact Information Call (toll free) iq.com Please visit us online at IQ.com for additional activities provided by Med IQ. 9
10 To receive credit, click the Get Credit tab at the bottom of the webcast for access to the evaluation, attestation, and post test. 217 Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors. 1
11 Abbreviations/Acronyms ACA = Affordable Care Act CMS = Centers for Medicare & Medicaid Services CNS = central nervous system FDA = Food and Drug Administration IM = intramuscular MAT = medication assisted therapy MD = medical doctor MMT = methadone maintenance NAS = Neonatal Abstinence Syndrome NCM = Nurse Care Manager NOWS = neonatal opioid withdrawal syndrome NTX = naltrexone OAT = opioid abuse treatment OBOT = office based opioid treatment OBOT B = office based opioid treatment with buprenorphine OTP = Opioid Treatment Program OUD = opioid use disorder SC = subcutaneous US = United States UTS = urine toxicology screen XR = extended release
Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationThe Changing Face of Heroin Use in the US: A Retrospective Analysis of the Past 50 Years 100 Heroin 90 Prescription opioids
Total Sample, % Total Sample, % The Changing Face of Heroin Use in the US: A Retrospective Analysis of the Past Years Heroin 9 Prescription opioids 8 7 6 96s 97s 98s 99s s s (n = 88) (n = ) (n = ) (n =
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationVirginia Opioid Addiction ECHO*
Virginia Opioid Addiction ECHO* Project ECHO: July 27th *ECHO: Extension of Community Healthcare Outcomes Agenda Agenda Agenda Introductions Clinical Director Administrative Medical Director ECHO Hubs
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationBuprenorphine and MAT 101
Buprenorphine and MAT 101 Why is Medication Assisted Treatment so Important for Recovery? KEN SAFFIER, MD 7 TH ANNUAL INTEGRATION SUMMIT DECEMBER 8, 2016 Disclosures: u Ken Saffier, MD, has nothing to
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationMAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
More informationOpioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective
Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective February 13, 2018 Frank Vocci, PhD New Therapies on the Horizon The planners, editors, faculty and reviewers of this activity
More informationNaltrexone Overview. Todd Korthuis, MD, MPH ECHO-MAT Conference February 14, 2017
Naltrexone Overview Todd Korthuis, MD, MPH ECHO-MAT Conference February 14, 2017 Pharmacotherapy for Opioid Use Disorder % Mu Receptor Intrinsic Activity 100 90 80 Full Agonist: Methadone ( How High )
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationUnderstanding Opioid Addiction and. Medication Assisted Treatment for. Families in the Child Welfare System
Understanding Opioid Addiction and Medication Assisted Treatment for Families in the Child Welfare System Medicine Jason B. Fields, MD, FASAM Associate Medical Director, DACCO Behavioral Health, Inc. President
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationQuestions & Answers About Probuphine. Here are the answers to some questions you may have about the Probuphine implant:
Questions & Answers About Probuphine Here are the answers to some questions you may have about the Probuphine implant: 1. Can my doctor prescribe and insert Probuphine? 2. What should I do after the Probuphine
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationAgenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationPOWER TO HELP REVERSE AN OPIOID OVERDOSE
POWER TO HELP REVERSE AN OPIOID OVERDOSE FDA APPROVED Concentrated 4 mg dose Needle-free; no assembly required Designed for ease-of-use in the community setting Requires no specialized training* Not a
More informationNaltrexone Overview. Todd Korthuis, MD, MPH ECHO-MAT Conference November 7, 2017
Naltrexone Overview Todd Korthuis, MD, MPH ECHO-MAT Conference November 7, 2017 Disclosure Information Speaker/Planner: Todd Korthuis, MD, has nothing to disclose. 2 Pharmacotherapy for Opioid Use Disorder
More informationOptimizing Opioid Dependence Treatment A Guideline for Pharmacists
Optimizing Opioid Dependence Treatment A Guideline for Pharmacists Module 3: Optimal Use of Methadone F e b r u a r y 2 0 1 5 Learning Objectives To know and understand the pathophysiology of substance
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationMedication for the Treatment of Addiction (MAT)
Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication
More informationPublic Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationOpioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine
Opioid Use Disorders and Pregnancy Marcela Smid, MD Maternal-Fetal Medicine UNIVERSITY OF UTAH HEALTH, 2017 OBJECTIVES Definitions Epidemiology Pharmacology Effects on pregnancy Screening Treatment CARE
More informationMedication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
More informationIt s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs
It s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs Ken Saffier, MD Maureen Strohm, MD May 7, 2017 Disclosures Ken Saffier, MD, has nothing
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationProbuphine. (buprenorphine implant) New Product Slideshow
Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:
More informationMAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationWelcome to the Braeburn Access Program for PROBUPHINE (buprenorphine) implant for subdermal
Welcome to the Braeburn Access Program for PROBUPHINE (buprenorphine) implant for subdermal administration CIII Dear Health Care Provider, Welcome to the Braeburn Access Program. As you are aware, Braeburn
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationImproving the Quality of Addiction Treatment
Improving the Quality of Addiction Treatment Expanding Access to Medication-Assisted Treatment in Residential Addiction Treatment Programs Webinar sponsored by RTI International January 18, 2018 RTI International
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationCombating the Crisis: Medication Assisted Treatment DISCLOSURES DISCLAIMER 2/15/2019
Combating the Crisis: Medication Assisted Treatment for Opioid Use Disorder Kiley Boeding, PharmD PGY I Pharmacy Resident Iowa City Veterans Affairs Healthcare System DISCLOSURES Dr. Boeding does not have
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #468 (NQF 3175): Continuity of Pharmacotherapy for Opioid Use Disorder (OUD) National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention and Treatment of Opioid
More informationDisclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond
Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationArizona s Opioid Epidemic
Arizona s Opioid Epidemic Rise in Heroin Addiction and the Dangers of Fentanyl Sara Salek, MD Chief Medical Officer Shana Malone, MS Clinical Initiatives Project Manager 1 Disclosures None The National
More informationOpioids and Opioid Addiction: Practical Management Approaches
Opioids and Opioid Addiction: Practical Management Approaches Yngvild Olsen, MD, MPH Medical Director Institutes for Behavior Resources Inc/REACH Health Services Conflict of Interest No financial or advisory
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationMedication Assisted Treatment as an alternative in Drug Courts*
Medication Assisted Treatment as an alternative in Drug Courts* National Drug Court Institute *portions of this presentation include adapted slides by Frances Levin, MD, Joshua Lee, MD, & Laurence Westreich,
More informationMETHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE
METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More informationCorporate Medical Policy
Corporate Medical Policy Buprenorphine Implant for Treatment of Opioid Dependence File Name: Origination: Last CAP Review: Next CAP Review: Last Review: buprenorphine_implant_for_treatment_of_opioid_dependence
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationClinical Policy Title: Methadone and naltrexone for opioid use disorder
Clinical Policy Title: Methadone and naltrexone for opioid use disorder Clinical Policy Number: 18.02.08 Effective Date: July 1, 2016 Initial Review Date: February 17, 2016 Most Recent Review Date: July
More informationArwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
More informationMedication Treatment and Opioid Use Disorder
Medication Treatment and Opioid Use Disorder Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBOT-B Boston Medical Center Disclosures I have no disclosures
More informationOFFICE-BASED OPIOID TREATMENT (OBOT)
Optum Behavioral Clinical Policy OFFICE-BASED OPIOID TREATMENT (OBOT) Policy Number: BH727BCPOBOT_022017 Effective Date: March, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationMedical Assisted Treatment of Opioid
Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationLatest Research on Addiction and Treatment
Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:
More informationOrexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients
Press release Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients Uppsala, Sweden, September 2, 2016 Orexo AB (publ.) announces that the REZOLV retrospective
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More information